Study of human urinary kallidinogenase in cerebral blood flow recovery

Human urinary kallidinogenase improves cerebral blood flow in stroke

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-15007508

Enrollment

Unknown

Registered

2015-12-02

Start date

2010-01-05

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral vascual diseases

Interventions

observe group:human urinary kallidinogenase

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed as acute cerebral infarction; 2. diffusion weighted magnetic resonance imaging (DWI) identified a new ischemic lesion; 3. no more than 3 days after onset; 4. ages are in 18-75 years old; 5. National Institutes of Health Stroke Scale (NIHSS) score ranged from 4 to 20; 6. computerized tomography (CT) scanning identified no cerebral hemorrhaging, cancer or trauma; 7. agreement on this study.

Exclusion criteria

Exclusion criteria: 1. severe cardiac dysfunction; 2. chronic liver disease; elevated aminotransferase (1.5 times more than normal); 3. elevated creatinine (1.5 times more than normal); 4. pregnancy or other hemorrhagic disease; 5. thrombolytic therapy within 1 week; 6. taking angiotensin-converting enzyme inhibitor (ACEI) orally within 24 h.

Design outcomes

Primary

Measure	Time frame
NIHSS;mRS;cerebral blood flow;cerebral blood volume;mean transit time;time to peak;	—

Countries

China

Contacts

Public ContactJia-chun Feng

jldxfengjc@126.com+86 13756661276

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026